The FDA created the Epi Pen crisis...of course.....

[2aguy]

And here we have a look at why you have an Epi pen crisis....and the FDA, the government is right there causing it....

Blog: Why Mylan Labs is being scapegoated by the Political class

The answers can be divided into regulatory overreach, market demand created by the regulators and the opaque nature of pricing within the drug distribution channels

In 2015, The FDA made a series of decisions that effectively led to limited options for patients needing epinephrine and created a virtual monopoly for Mylan Labs.

This was accomplished by stiff-arming Adamis Corporation’s pre- filled epinephrine syringe, asking for more data and demanding an
expanded patient usability study including product stress testing before the original application.

Back in November 2015, France based Sanofi Corporation’s Auvi-Q product hit a wall, when an injector fault triggered a hefty recall.

Ultimately, the pharmaceutical giant yanked Auvi-Q from the market, More recently, the FDA handed generics giant Teva Pharmaceutical a rejection for its generic version of EpiPen, flagging “certain major deficiencies” in its letter to the Israeli pharmaceutical corporation. With serious issues to work through, Teva said earlier this year that it expects its product to be "significantly delayed" -- meaning it doesn’t expect a rollout before 2017.



Read more: Blog: Why Mylan Labs is being scapegoated by the Political class
Follow us: @AmericanThinker on Twitter | AmericanThinker on Facebook

 

[CrusaderFrank]

It's Democrats using government to enrich themselves, their supporters and friend.

 

[Hutch Starskey]

The FDA created the Epi Pen crisis...of course.....

Of course. We all know it's really just just the beginning of the program to get our guns.

 

[Manonthestreet]

by god single payer is the only thing that will saaavee us.......uummmmm uuummmmm

 

[2aguy]

Still...does anyone know how much money Mylan gave to the clinton foundation?

 

[Penelope]

And here we have a look at why you have an Epi pen crisis....and the FDA, the government is right there causing it....

Blog: Why Mylan Labs is being scapegoated by the Political class

The answers can be divided into regulatory overreach, market demand created by the regulators and the opaque nature of pricing within the drug distribution channels

In 2015, The FDA made a series of decisions that effectively led to limited options for patients needing epinephrine and created a virtual monopoly for Mylan Labs.

This was accomplished by stiff-arming Adamis Corporation’s pre- filled epinephrine syringe, asking for more data and demanding an
expanded patient usability study including product stress testing before the original application.

Back in November 2015, France based Sanofi Corporation’s Auvi-Q product hit a wall, when an injector fault triggered a hefty recall.

Ultimately, the pharmaceutical giant yanked Auvi-Q from the market, More recently, the FDA handed generics giant Teva Pharmaceutical a rejection for its generic version of EpiPen, flagging “certain major deficiencies” in its letter to the Israeli pharmaceutical corporation. With serious issues to work through, Teva said earlier this year that it expects its product to be "significantly delayed" -- meaning it doesn’t expect a rollout before 2017.



Read more: Blog: Why Mylan Labs is being scapegoated by the Political class
Follow us: @AmericanThinker on Twitter | AmericanThinker on Facebook

So why did Mylan have to raise the price so much??

 

[Harry Dresden]

And here we have a look at why you have an Epi pen crisis....and the FDA, the government is right there causing it....

Blog: Why Mylan Labs is being scapegoated by the Political class

The answers can be divided into regulatory overreach, market demand created by the regulators and the opaque nature of pricing within the drug distribution channels

In 2015, The FDA made a series of decisions that effectively led to limited options for patients needing epinephrine and created a virtual monopoly for Mylan Labs.

This was accomplished by stiff-arming Adamis Corporation’s pre- filled epinephrine syringe, asking for more data and demanding an
expanded patient usability study including product stress testing before the original application.

Back in November 2015, France based Sanofi Corporation’s Auvi-Q product hit a wall, when an injector fault triggered a hefty recall.

Ultimately, the pharmaceutical giant yanked Auvi-Q from the market, More recently, the FDA handed generics giant Teva Pharmaceutical a rejection for its generic version of EpiPen, flagging “certain major deficiencies” in its letter to the Israeli pharmaceutical corporation. With serious issues to work through, Teva said earlier this year that it expects its product to be "significantly delayed" -- meaning it doesn’t expect a rollout before 2017.



Read more: Blog: Why Mylan Labs is being scapegoated by the Political class
Follow us: @AmericanThinker on Twitter | AmericanThinker on Facebook

So why did Mylan have to raise the price so much??

that is the question aint it?....they cant site research costs on this one....

 

[Penelope]

The ceo blamed it on Obamacare that due to high deductibles people are now more aware of what they are paying.

I guess that is a good thing, people don't seem to care as long as insurance companies pay, but the insurance companies get a drop in price, but when consumers have to pay, we get upset.

I guess we need to go to government healthcare and get rid of the insurance companies, then the government will step in an stop this price gouging. Everyone under the same plan , and the elites can stand in line like everyone else.

Google wiki article
In 2007, Mylan secured rights to the nearly 50-year old EpiPen, used to treat anaphylaxis (severe allergic reactions).[4] Bresch advocated for broader availability of EpiPens in public places and helped pass the School Access to Emergency Epinephrine Act which made epinephrine more accessible in schools.[18][30] Between 2009 and May 2016, under Bresch's tenure as Mylan president, Mylan raised the price of a set of pens by nearly 500 percent, from $103.50 to $608.61.[4] Proxy filings show that from 2007 to 2015, Bresch's compensation went from $2,453,456 to $18,931,068, a 671 percent increase. During the same period, EpiPen prices went from $56.64 to $317.82, a 461 percent increase, according to data provided by Connecture.[31]